What is Complement Therapeutics?
Complement Therapeutics is a specialized biotechnology enterprise dedicated to the development of novel therapeutic interventions targeting the Complement System. The company focuses on addressing high-unmet clinical needs, particularly in the realm of age-related macular degeneration and other complement-related pathologies. By integrating advanced AAV gene therapy modalities with protein-based research, the firm aims to transform patient outcomes through precision medicine. Its lead candidate, CTx001, currently in pre-clinical development for Geographic Atrophy, serves as the cornerstone of its R&D strategy, reflecting a commitment to scientific rigor and long-term value creation within the global life sciences sector.
How much funding has Complement Therapeutics raised?
Complement Therapeutics has raised a total of $84.7M across 2 funding rounds:
Angel/Seed
$5.7M
Series A
$79M
Angel/Seed (2022): $5.7M with participation from BGV (BioGeneration Ventures and Forbion
Series A (2023): $79M led by Generate BioVentures, Panakes Partners, Seroba Life Sciences Management, Forbion, Gimv, Hadean Ventures, and Cambridge Innovation Capital
Key Investors in Complement Therapeutics
BGV (BioGeneration Ventures)
A venture capital firm specializing in seed investments for early-stage life science companies, with a focus on accelerating product development for high unmet medical needs.
Forbion
A global life sciences venture capital firm that guides biotech and biopharmaceutical companies from early-stage research through clinical development.
Generate BioVentures
An investment firm providing innovative solutions and financial backing for synthetic biology and genetic engineering initiatives.
What's next for Complement Therapeutics?
With the successful closure of this major enterprise-level funding, Complement Therapeutics is poised to transition its lead assets into more advanced clinical stages. The strategic allocation of these funds will likely prioritize the expansion of its R&D infrastructure and the acceleration of its gene therapy programs. As the company continues to refine its therapeutic platforms, it remains focused on navigating the complex regulatory landscape of the biotech industry. Future growth will be contingent upon the successful translation of its pre-clinical data into human clinical trials, a critical phase that will determine the long-term commercial viability of its innovative treatment portfolio.
See full Complement Therapeutics company page
